On the evening of July 2nd, numerous listed companies released a flurry of announcements detailing significant business developments.

These disclosures spanned a wide range of sectors including biopharmaceuticals, computing power, automotive parts, new energy, photovoltaics, and coal, covering areas such as business cooperation, project wins, industrial investment, refinancing, and positive operational updates.

Regarding contracts and strategic partnerships, a controlling subsidiary of CSPC PHARMA has entered into a deep strategic collaboration with AstraZeneca PLC focused on a novel small interfering RNA drug candidate.

Concurrently, the candidate drug SYS6043 has been included in the Breakthrough Therapy Designation list.

Dongan Power secured a total of 12 supply agreements from 8 customers in the second quarter, expanding its downstream market.

Yunnan Energy Investment obtained the development rights for the second phase of the Dalongshan Wind Farm in Huaning County.

A controlling subsidiary of Digital China Group Co.,Ltd. successfully won a bid for China Mobile's centralized PC server procurement project.

Significant industrial investments continued to materialize.

Tengjing Technology plans to invest 35 million yuan to establish a wholly-owned subsidiary, consolidating its AR consumer optics business.

TCL Zhonghuan is advancing the upgrade and renovation of its BC cell and module production base, strengthening its photovoltaic capacity layout.

Lvfa Power added 960 MW of new energy project construction indicators in the first half of the year, continuing to expand its clean energy portfolio.

Refinancing channels are broadening, with Muyuan Foodstuff receiving regulatory approval to register an 8 billion yuan debt financing instrument, which will help optimize the company's capital structure.

Other positive operational announcements were also disclosed.

Forest Packaging's subsidiary received a value-added tax refund of 14.4951 million yuan for resource comprehensive utilization.

Chengda Biological obtained the drug registration certificate for its trivalent influenza vaccine and passed the GMP compliance inspection.

Vanke A appointed Huang Yu as the company's president.

China Shenhua's two power generation units in Dingzhou and Cangdong successfully passed the 168-hour trial operation, formally meeting the conditions for stable commercial operation.